🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Shares

Deutsche Bank cuts Novo Nordisk stock target, keeps Buy rating on Q3 results

EditorNatashya Angelica
Published 08/11/2024, 03:02 am
NOVOb
-
NVO
-

On Thursday, an analyst from Deutsche Bank (ETR:DBKGn) adjusted the price target for Novo Nordisk (CSE:NOVOb) (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care, to DKK1,000.00, down from the previous DKK1,100.00. Despite this reduction, the analyst maintained a Buy rating on the company's stock.

The adjustment follows the analyst's review of Novo Nordisk's third-quarter performance and the market's reaction to the company's financial guidance. Earlier in the day, Novo Nordisk's shares experienced a significant uptick, which the analyst described as "rather generous" in light of some nuanced considerations that were highlighted in their initial review.

The market, however, retracted its initial positive response during a call where Novo Nordisk provided a forward-looking statement on its revenue outlook for the fiscal year 2025. The company indicated an expectation of high-teens revenue growth for FY25, which, according to Deutsche Bank's and consensus models, was consistent with the projected growth of +19/20% that had been estimated that morning.

Despite this, the market interpreted the guidance differently, leading to a retraction of the earlier rally. The Deutsche Bank analyst suggested that the market's reaction to the FY25 guidance comment was somewhat misguided, as the directional outlook should have been seen as a reaffirmation of the current estimates.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.